250 related articles for article (PubMed ID: 37915617)
1. Evidence to Date: Clinical Utility of Tremelimumab in the Treatment of Unresectable Hepatocellular Carcinoma.
Ahmed Z; Lee SS; Victor DW; Kodali S
J Hepatocell Carcinoma; 2023; 10():1911-1922. PubMed ID: 37915617
[TBL] [Abstract][Full Text] [Related]
2. Tremelimumab: A Review in Advanced or Unresectable Hepatocellular Carcinoma.
France NL; Blair HA
Target Oncol; 2024 Jan; 19(1):115-123. PubMed ID: 38236364
[TBL] [Abstract][Full Text] [Related]
3. Tremelimumab: First Approval.
Keam SJ
Drugs; 2023 Jan; 83(1):93-102. PubMed ID: 36571670
[TBL] [Abstract][Full Text] [Related]
4. Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma.
Tümen D; Heumann P; Gülow K; Demirci CN; Cosma LS; Müller M; Kandulski A
Biomedicines; 2022 Dec; 10(12):. PubMed ID: 36551958
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation.
Katariya NN; Lizaola-Mayo BC; Chascsa DM; Giorgakis E; Aqel BA; Moss AA; Uson Junior PLS; Borad MJ; Mathur AK
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565184
[TBL] [Abstract][Full Text] [Related]
6. Tremelimumab and durvalumab in the treatment of unresectable, advanced hepatocellular carcinoma.
de Castria TB; Khalil DN; Harding JJ; O'Reilly EM; Abou-Alfa GK
Future Oncol; 2022 Oct; 18(33):3769-3782. PubMed ID: 36399155
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma.
Uson Junior PLS; Liu AJ; Sonbol MB; Borad MJ; Bekaii-Saab TS
Chin Clin Oncol; 2021 Feb; 10(1):11. PubMed ID: 33541088
[TBL] [Abstract][Full Text] [Related]
8. Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review.
Ahmed F; Onwumeh-Okwundu J; Yukselen Z; Endaya Coronel MK; Zaidi M; Guntipalli P; Garimella V; Gudapati S; Mezidor MD; Andrews K; Mouchli M; Shahini E
World J Gastrointest Oncol; 2021 Nov; 13(11):1813-1832. PubMed ID: 34853653
[TBL] [Abstract][Full Text] [Related]
9. Systemic Therapy in Advanced Hepatocellular Carcinoma: Patient Selection and Key Considerations.
Storandt MH; Mahipal A; Tella SH; Kommalapati A; Jin Z
J Hepatocell Carcinoma; 2022; 9():1187-1200. PubMed ID: 36471742
[TBL] [Abstract][Full Text] [Related]
10. Systemic Therapy for Advanced Hepatocellular Carcinoma: An Update of a Rapidly Evolving Field.
Doycheva I; Thuluvath PJ
J Clin Exp Hepatol; 2019; 9(5):588-596. PubMed ID: 31695249
[TBL] [Abstract][Full Text] [Related]
11. New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma.
Kudo M
Int J Clin Oncol; 2022 Jul; 27(7):1110-1119. PubMed ID: 35527313
[TBL] [Abstract][Full Text] [Related]
12. Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.
Kelley RK; Sangro B; Harris W; Ikeda M; Okusaka T; Kang YK; Qin S; Tai DW; Lim HY; Yau T; Yong WP; Cheng AL; Gasbarrini A; Damian S; Bruix J; Borad M; Bendell J; Kim TY; Standifer N; He P; Makowsky M; Negro A; Kudo M; Abou-Alfa GK
J Clin Oncol; 2021 Sep; 39(27):2991-3001. PubMed ID: 34292792
[TBL] [Abstract][Full Text] [Related]
13. Hepatocellular Carcinoma: Advances in Systemic Therapy.
Selene II; Ozen M; Patel RA
Semin Intervent Radiol; 2024 Feb; 41(1):56-62. PubMed ID: 38495258
[TBL] [Abstract][Full Text] [Related]
14. Goals and targets for personalized therapy for HCC.
Couri T; Pillai A
Hepatol Int; 2019 Mar; 13(2):125-137. PubMed ID: 30600478
[TBL] [Abstract][Full Text] [Related]
15. The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma.
Lee MMP; Chan LL; Chan SL
J Liver Cancer; 2023 Sep; 23(2):262-271. PubMed ID: 37589044
[TBL] [Abstract][Full Text] [Related]
16. Durvalumab: an investigational agent for unresectable hepatocellular carcinoma.
Maestri M; Pallozzi M; Santopaolo F; Cerrito L; Pompili M; Gasbarrini A; Ponziani FR
Expert Opin Investig Drugs; 2022 Apr; 31(4):347-360. PubMed ID: 35072571
[TBL] [Abstract][Full Text] [Related]
17. First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Patient-Level Network Meta-Analysis.
Fong KY; Zhao JJ; Sultana R; Lee JJX; Lee SY; Chan SL; Yau T; Tai DWM; Sundar R; Too CW
Liver Cancer; 2023 Feb; 12(1):7-18. PubMed ID: 36872922
[TBL] [Abstract][Full Text] [Related]
18. Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond.
Feng MY; Chan LL; Chan SL
Curr Oncol; 2022 Aug; 29(8):5489-5507. PubMed ID: 36005172
[TBL] [Abstract][Full Text] [Related]
19. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.
Duffy AG; Ulahannan SV; Makorova-Rusher O; Rahma O; Wedemeyer H; Pratt D; Davis JL; Hughes MS; Heller T; ElGindi M; Uppala A; Korangy F; Kleiner DE; Figg WD; Venzon D; Steinberg SM; Venkatesan AM; Krishnasamy V; Abi-Jaoudeh N; Levy E; Wood BJ; Greten TF
J Hepatol; 2017 Mar; 66(3):545-551. PubMed ID: 27816492
[TBL] [Abstract][Full Text] [Related]
20. The New Era of Systemic Treatment for Hepatocellular Carcinoma: From the First Line to the Optimal Sequence.
Cerreto M; Cardone F; Cerrito L; Stella L; Santopaolo F; Pallozzi M; Gasbarrini A; Ponziani FR
Curr Oncol; 2023 Sep; 30(10):8774-8792. PubMed ID: 37887533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]